RecruitingPhase 3NCT06668181
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Studying Psoriasis-related juvenile idiopathic arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UCB Biopharma SRL
- Principal Investigator
- UCB Cares001 844 599 2273
- Intervention
- Bimekizumab(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 2-18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (23)
- Ja0005 50646, Calgary, Canada
- Ja0005 50644, Montreal, Canada
- Ja0005 50645, Saskatoon, Canada
- Ja0005 40777, Indre-et-Loire, France
- Ja0005 40510, Le Kremlin-Bicêtre, France
- Ja0005 40778, Paris, France
- Ja0005 40776, Poitiers, France
- Ja0005 40369, Berlin, Germany
- Ja0005 40356, Dresden, Germany
- Ja0005 40072, Freiburg im Breisgau, Germany
- Ja0005 40852, Hamburg, Germany
- Ja0005 40787, Sankt Augustin, Germany
- Ja0005 40779, Sendenhorst, Germany
- Ja0005 40427, Tübingen, Germany
- Ja0005 40720, Krakow, Poland
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06668181 on ClinicalTrials.govOther trials for Psoriasis-related juvenile idiopathic arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06751238Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Novartis Pharmaceuticals
- RECRUITINGPHASE3NCT06869551A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisBristol-Myers Squibb
- RECRUITINGPHASE3NCT06100744A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabAbbVie
- RECRUITINGPHASE3NCT05767047A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisAmgen
- ACTIVE NOT RECRUITINGPHASE3NCT05083182A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisJanssen Research & Development, LLC
- RECRUITINGPHASE3NCT04804553Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisAmgen
- ACTIVE NOT RECRUITINGPHASE3NCT04527380A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisEli Lilly and Company
See all trials for Psoriasis-related juvenile idiopathic arthritis →